SCHEMBL23979593

SCHEMBL23979593

Cc1nc2ccc(F)cc2c(=O)n1C1CCCC(=O)NC1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 7/20 0.62
CRBN Q96SW2 7/20 0.62
TNF P01375 1/20 0.50
IL1B P01584 1/20 0.50
IKZF3 Q9UKT9 1/20 0.50
HRH3 Q9Y5N1 2/20 0.42
KCNH2 Q12809 2/20 0.41
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
POLB P06746 1/20 0.40
CASP3 P42574 1/20 0.39
CYP2D6 P10635 1/20 0.39
GHSR Q92847 1/20 0.39
IDO1 P14902 2/20 0.37
TDO2 P48775 2/20 0.37
IDO2 Q6ZQW0 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
GLA P06280 1/20 0.36
AADAT Q8N5Z0 1/20 0.36
ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3654727 0.93 CRBN (0.71) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979390 0.91 CRBN (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979424 0.87 CRBN (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979366 0.87 DDB1 (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979373 0.87 CRBN (0.62) DDB1CRBNTNFIL1BIKZF3
SCHEMBL30137405 0.84 CRBN (0.71) DDB1CRBNTNFIL1BIKZF3
SCHEMBL3653177 0.84 CRBN (0.71) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979419 0.84 DDB1 (0.59) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979477 0.83 DDB1 (0.67) DDB1CRBNTNFIL1BIKZF3
SCHEMBL23979411 0.82 CRBN (0.65) DDB1CRBNTNFIL1BIKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885TNF 2820/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885TNF 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.